Back to search

McMaster University

Enhancing Oncolytic Immunotherapy through Induction of Immunogenic Cell Death

Abstract

dc:description.abstract

Oncolytic viruses (OVs) are natural or engineered viruses that specifically infect and kill cancer cells without harming healthy tissues. Cancer cells killed by OV infection expose tumor antigens along with viral components and intracellular factors that mediate inflammation. Ideally, this process elicits an anti-tumor immune response that controls tumor growth. Herpes simplex virus type 1 (HSV-1) is a candidate OV that has proven therapeutic efficacy in preclinical cancer models. However, therapeutic efficacy of current oncolytic HSV-1 (oHSV-1) is limited in immunologically hot cancers such as melanoma. Here we showed that oHSV-1 expressing a modified B-box (HMB) of high mobility group box 1 (HMGB1), a potent ligand of toll-like receptor (TLR) 4-MD2, provides marginal therapeutic benefit in mice bearing breast cancer. Comparing with parental oHSV, tumor-bearing mice treated with oHSV-1-HMB showed improved survival and reduced tumor burden. Our results demonstrated the potential to improve oHSV-1 with immunogenic cell death modulators. We anticipate our oHSV-1-HMB to provide additive benefit with the combination of immunological checkpoint blockade.

Degree

thesis:*
Department dc:contributor.department
Biochemistry
Year dc:date.issued
2019

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wei, Jiarun
Advisor dc:contributor.advisor
  • Mossman, Karen

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
McMaster University
Base URL
macsphere.mcmaster.ca/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Wei, Jiarun. Enhancing Oncolytic Immunotherapy through Induction of Immunogenic Cell Death. 2019. http://hdl.handle.net/11375/24863